ChartRow logo
Data provided bySource: Twelve Data
NBIX
$165.92+0.37%
as of close, Nov 17, 2026
☾ AH $165.92 +0.37%
Share this page

NBIX — Neurocrine Biosciences Inc. price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
Data provided bySource: Twelve Data
What would $1,000 invested in NBIX be worth today? →
NBIX returns: By year · By month · By week · Trailing

Price data

Price
$165.92
YTD price return
+16.99%
YTD total return
+16.99%
Market cap
16.8B
Enterprise value
16.6B
Shares outstanding
101.2M
52W low
$122.14
52W high
$186.12
From 52W high
-10.85%
From 52W low
+35.84%
52W range
68%$122–$186
Beta
0.39

Volume

Rel volume
0.81×
30D volume
1.4M
30D $ vol
210.9M

Insider trading

Insider net 1W
none
Insider net 1M
−$2.3M
Insider net 3M
−$3.2M
Insider net 1Y
−$70.4M

Form 4 transactions by trade date, as filed; latest on file 2026-11-03.

Fundamentals

Sales (ttm)
3.7B
Sales/share
$36.57
EPS (ttm)
$6.74
FCF (ttm)
1B
FCF/share
$10.27
Book value/share
$38.32
Net margin
18.98%
ROE
18.11%
ROA
12.48%
Current ratio
2.04

Growth (CAGR, ttm) · 10Y

Sales
+38.01%+27.54%+28.19%+73.49%
Net income
+64.19%+54.35%+9.57%n/a
FCF
+75.37%+39.28%+25.97%n/a
Shares
+1.52%+1.00%+1.30%+1.54%

Per-share growth (CAGR, ttm) · 10Y

EPS
+61.04%+52.13%+8.09%n/a
Sales/share
+35.95%+26.28%+26.54%+70.85%
FCF/share
+72.74%+37.91%+24.35%n/a
Book value/share
+27.23%+23.43%+21.99%+25.21%
Price
+15.59%+15.05%+13.12%+12.44%
Total return
+15.59%+15.05%+13.12%+12.44%

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
24.6×
P/OI (ttm)
18.9×
Fwd P/E
13.6×
P/S (ttm)
4.5×
P/B (mrq)
4.3×
P/FCF (ttm)
16.2×
EV/EBITDA (fy)
17.1×
EV/Sales (ttm)
4.5×
FCF yield (ttm)
6.19%
Buyback yield (realized, 1y)
-1.52%
Shareholder yield (realized, 1y)
-1.52%
Buyback yield (cash, ttm)
-0.08%
Shareholder yield (cash, ttm)
-0.08%

Vs own 10Y history

P/E
14th
P/OI
3rd
P/S
4th
P/B
8th
P/FCF
2nd

Bar = where today’s multiple sits in NBIX’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-17#

Data provided bySource: Twelve Data
1D
+0.37%
5D
-1.90%
1M
+22.26%
3M
+7.40%
YTD
+16.99%
1Y
+15.58%
5Y
+85.18%
1D
+0.37%
5D
-1.90%
1M
+22.26%
3M
+7.40%
YTD
+16.99%
1Y
+15.58%
5Y
+85.18%

Fundamentals#

Revenue

5Y CAGR +22.3%10Y CAGR +64.5%YoY +41.2%
$3.7B TTM$1.1B Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y CAGR +30.6%10Y n/mYoY +38.6%
$887.1M TTM$331.3M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y CAGR +2.3%10Y n/mYoY −3.9%
$6.74 TTM$1.96 Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y CAGR +28.0%10Y n/mYoY +79.0%
$1B TTM$383.6M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

TTM: operating cash flow $1.1B, capex −$26.1M

Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Q3 2026: operating cash flow $395.2M, capex −$11.6M

Shares (diluted)

5Y +4.8%10Y +21.3%YoY +2.6%
104.2M TTM105.2M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y CAGR +3.3%10Y n/mYoY −1.4%
$702.5M TTM$206.5M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Full NBIX financials →

About Neurocrine Biosciences#

Data provided bySource: Twelve Data

Neurocrine Biosciences, Inc. is a neuroscience-focused biopharmaceutical company that discovers, develops, and commercializes medicines for neurological, neuroendocrine, and neuropsychiatric disorders. Its current portfolio includes treatments for movement disorders such as tardive dyskinesia and Huntington’s disease chorea, as well as therapies for endocrine conditions including congenital adrenal hyperplasia, endometriosis, and uterine fibroids. The company also maintains a clinical-stage pipeline spanning additional neuroscience and endocrine targets, with research programs aimed at addressing underserved patient populations. Neurocrine Biosciences, Inc. plays an important role in specialty pharmaceuticals by combining marketed products with ongoing drug development across complex, chronic conditions that often require long-term management. Headquartered in San Diego, California, it serves patients and healthcare providers in the United States and internationally through its commercial operations and development activities.

San Diego, CA·2,500 employees·Drug Manufacturers - Specialty & Generic·neurocrine.com·As of Oct 28, 2026

Recent filings#

All filings and insider trades →

ETFs holding NBIX#

29 of the 193 ETFs ChartRow carries live hold NBIX. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Jul 26).

FundNameFiled weight
IBBiShares Biotechnology ETF1.3%
XBISPDR S&P Biotech ETF1.0%
VBKVanguard Small-Cap Growth ETF0.5%
IJHiShares Core S&P Mid-Cap ETF0.5%
MDYSPDR S&P MidCap 400 ETF Trust0.5%
IWPiShares Russell Mid-Cap Growth ETF0.4%
COWZPacer US Cash Cows 100 ETF0.3%
VBVanguard Small-Cap ETF0.2%
TickerName1M1D
LLYEli Lilly and Company+12.61%-1.13%
JNJJohnson & Johnson+9.05%-1.36%
ABBVAbbVie Inc.+2.59%-0.59%
MRKMerck & Co. Inc.-1.77%-0.75%
UNHUnitedHealth Group Incorporated Common Stock (DE)-2.93%-5.42%
NVSNovartis AG+5.65%-0.67%
TMOThermo Fisher Scientific Inc.-0.47%-0.66%
AMGNAmgen Inc.+5.88%-0.95%